Table 1.

Comparison of SGLT2 inhibitor trials on functional outcomes and quality of life in patients with chronic heart failure

	EMPERIAL-Preserved	EMPERIAL-Reduced	DETERMINE-Preserved	DETERMINE-Reduced
Study drug	Empagliflozin 10 mg qd		Dapagliflozin 10 mg qd
Sample size	300	300	400	300
Key inclusion criteria	Chronic HF NYHA class II−IV Walking distance in the 6MWT ≤ 350 m		Chronic HF NYHA class II−IV Walking distance in the 6MWT ≥ 100 to ≤ 425 m
	HFpEF (LVEF > 40%)	HFrEF (LVEF ≤ 40%)	HFpEF (LVEF > 40%)	HFrEF (LVEF ≤ 40%)
Primary endpoint	Change from baseline to week 12 in exercise capacity (6MWT)		Change from baseline to week 16 in exercise capacity (6MWT)

NYHA New York Heart Association, 6MWT 6-min walk test, HFpEF heart failure with preserved ejection fraction, HFrEF heart failure with reduced ejection fraction, LVEF left ventricular ejection fraction